Cancer BiologybioRxivPreprint
Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent
F. Spriano, L. Aresu, L. Cascione…·F. Bertoni
This study evaluates lisavanbulin's anti-lymphoma activity and EB1 expression in DLBCL, showing potent in vitro cytotoxicity and potential clinical relevance.
DOI 10.1101/2022.12.31.521730